EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor

Yang Li, Canhua Liang, Ziwei Feng, Shaohuan Lu, GuangZhao Wang, Guangyi Meng

Frontiers in Oncology · 13.05.2026 · 16

DOI: 10.3389/fonc.2026.1804448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 13.05.2026. Verfasst von Yang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus (VZV). Cancer patients, due to immune suppression, are at an increased risk of HZ. However, the exact relationship between cancer and the occurrence of HZ remains unclear.

Methods

This retrospective study collected data from cancer patients diagnosed between 01/01/2020, and 30/09/2024. Descriptive statistics were used to summarize the clinical characteristics of HZ patients. Propensity score matching (PSM) was applied to match HZ and non-HZ groups in a 1:3 ratio, controlling for potential confounding factors. Logistic regression analysis was performed to investigate the impact of cancer type, treatment modalities, and other factors on the occurrence of HZ.

Results

Among 99 HZ patients, the onset of HZ was closely associated with the timing of anticancer treatment, with 89.89% of patients developing HZ within 12 months after the first anticancer therapy. After PSM matching, cancer type was identified as a significant independent risk factor for HZ. Patients with hematologic cancers, such as multiple myeloma, had a significantly higher risk of developing HZ compared to those with solid tumors (OR = 2.41, 95% CI 1.11-5.24, P = 0.03).

Conclusions

Hematologic malignancy patients are at a significantly higher risk of developing HZ compared to those with solid tumors. The use of immune checkpoint inhibitors (ICIs) did not significantly increase the risk of HZ. These findings suggest that patients with hematologic cancers should be closely monitored for HZ and undergo preventive measures.

Schlagwörter

Stichwörter der Autor:innen

factor influencinghematologic cancersherpes zostermalignant tumorpropensity score matching

Autor:innen und Institutionen

  • Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China.

Zitieren

APA

Li, Y., Liang, C., Feng, Z., Lu, S., Wang, G., & Meng, G. (2026). A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1804448

Vancouver

Li Y, Liang C, Feng Z, Lu S, Wang G, Meng G. A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1804448

BibTeX
@article{Li2026,
  author = {Li, Yang and Liang, Canhua and Feng, Ziwei and Lu, Shaohuan and Wang, GuangZhao and Meng, Guangyi},
  title = {A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1804448}
}
Kostenlos starten →